Evercore ISI analysts upgraded CRISPR Therapeutics stock from an In Line to an Outperform rating and increased the price target significantly to $99 from the previous $60. The upgrade comes as ...

Evercore ISI analyst Kirk Materne maintained a Hold rating on Tyler Technologies (TYL – Research Report) yesterday and set a price target of ...

Evercore ISI analyst David Palmer maintained a Buy rating on Restaurant Brands International (QSR – Research Report) yesterday and set a price ...

Evercore ISI made an adjustment to its price target for Lyft stock (NASDAQ:LYFT), reducing it to $15.00 from the previous $19 ...

Confluent (NASDAQ:CFLT – Get Free Report) had its target price upped by Evercore ISI from $32.00 to $40.00 in a report ...

Walgreens Chief Executive Officer Tim Wentworth reiterated on an earnings call last month that the company plans to divest ...

Zillow Group (NASDAQ:ZG – Get Free Report) had its target price boosted by equities research analysts at Evercore ISI from $75.00 to $90.00 in a research report issued on Wednesday,Benzinga reports.

Nvidia (NASDAQ:NVDA) was added to Evercore ISI's Tactical Outperform list on Monday as analysts turned bullish ahead of the company's fiscal fourth-quarter earnings report on February 26.

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.

Riot Platforms is expanding into AI and high-performance computing partnerships while adding three new board members with ...